Clinical Trial Update: pazopanib_NCRCC,Ph2 STUDY [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of pazopanib for locally advanced or metastatic non-clear cell renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-clear Cell Renal Cell Carcinoma

Drugs mentioned

• Votrient (Pazopanib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Locally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma | Phase 2 | Status: COMPLETED